Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Executive summary Liver diseases have become a major health threat across Europe, and
the face of European hepatology is changing due to the cure of viral hepatitis C and the …

Nonalcoholic fatty liver disease (NAFLD) is a dynamic chronic liver disease that develops in
close association with metabolic irregularities. Between 2016 and 2019, the global …

Over the last two decades, there have been tremendous advances in the non-invasive
diagnosis and risk stratification of chronic liver diseases (CLDs). Non-invasive approaches …

Methods Prevalence data from 245 articles involving 2,699,627 persons were used with a
hierarchical Bayesian approach to forecast the prevalence of NAFLD through 2040 …

Background Given the association of NAFLD with metabolic risks, a name change to MAFLD
is proposed. We compared the long‐term outcomes of NAFLD and MAFLD. Methods We …

Background The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing in
parallel with obesity and type 2 diabetes. Aim To review the global epidemiology of NAFLD …

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most
common chronic liver disease globally, affecting more than a third of the world's adult …

OBJECTIVE Most people with type 2 diabetes (T2DM) and nonalcoholic steatohepatitis
(NASH) or advanced fibrosis (AF) remain undiagnosed, resulting in missed opportunities for …